Lori Anne Kunkel, Director, on June 05, 2026, sold 10,000 shares in Enliven Therapeutics (ELVN) for $345,351. Following the Form 4 filing with the SEC, Kunkel has control over a total of 51,884 common shares of the company, with 51,884 shares held directly.
SEC Filing: